VTRS

SEC source: 0000899243-20-031554 · doc4.xml · derivative · entry 5

KORMAN HARRY · CIK 0001197548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,446

Underlying: Common Stock · 3,446 shares

Expires 2028-06-29

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F8 · derivative.exercise_date: These options vested on March 2, 2019.

SEC source: 0000899243-20-031554 · doc4.xml · derivative · entry 4

KORMAN HARRY · CIK 0001197548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,555

Underlying: Common Stock · 12,555 shares

Expires 2024-03-05

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F7 · derivative.exercise_date: These options vested on March 5, 2017.

SEC source: 0000899243-20-031554 · doc4.xml · derivative · entry 3

KORMAN HARRY · CIK 0001197548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,266

Underlying: Common Stock · 4,266 shares

Expires 2022-02-22

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F6 · derivative.exercise_date: These options vested on February 22, 2015.

SEC source: 0000899243-20-031554 · doc4.xml · derivative · entry 2

KORMAN HARRY · CIK 0001197548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,413

Underlying: Common Stock · 4,413 shares

Expires 2021-03-02

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F5 · derivative.exercise_date: These options vested on March 2, 2014.

SEC source: 0000899243-20-031554 · doc4.xml · nonDerivative · entry 1

KORMAN HARRY · CIK 0001197548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,701

F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

F3 · balance_after: Includes 186 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 15

Malik Rajiv · CIK 0001388111 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,369

Underlying: Common Stock · 197,369 shares

Expires not disclosed

F11 · security: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F12 · price: Received in exchange for, and having substantially the same terms as (other than no longer being subject to the performance-based vesting conditions), performance restricted stock units of Mylan in connection with the Combination.

F18 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2023.

F18 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2023.

SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 14

Malik Rajiv · CIK 0001388111 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,895

Underlying: Common Stock · 157,895 shares

Expires not disclosed

F9 · security: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021.

F10 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F17 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. 52,632 of the RSUs will vest on March 2, 2021, 52,631 will vest on March 2, 2022 and 52,632 will vest on March 2, 2023.

F17 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. 52,632 of the RSUs will vest on March 2, 2021, 52,631 will vest on March 2, 2022 and 52,632 will vest on March 2, 2023.

SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 13

Malik Rajiv · CIK 0001388111 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,871

Underlying: Common Stock · 84,871 shares

Expires 2030-03-02

F3 · security: Includes 620 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F16 · derivative.exercise_date: 28,291 of these options will vest on March 2, 2021 and 28,290 will vest on each of March 2, 2022 and March 2, 2023.

SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 12

Malik Rajiv · CIK 0001388111 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,684

Underlying: Common Stock · 125,684 shares

Expires not disclosed

F11 · security: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F12 · price: Received in exchange for, and having substantially the same terms as (other than no longer being subject to the performance-based vesting conditions), performance restricted stock units of Mylan in connection with the Combination.

F15 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2022.

F15 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2022.

SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 11

Malik Rajiv · CIK 0001388111 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,031

Underlying: Common Stock · 67,031 shares

Expires not disclosed

F9 · security: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021.

F10 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F14 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. 33,515 of the RSUs will vest on March 2, 2021 and 33,516 will vest on March 2, 2022.

F14 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. 33,515 of the RSUs will vest on March 2, 2021 and 33,516 will vest on March 2, 2022.

SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 10

Malik Rajiv · CIK 0001388111 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,053

Underlying: Common Stock · 60,053 shares

Expires 2029-03-01

F3 · security: Includes 620 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F13 · derivative.exercise_date: 20,018 of these options vested on March 2, 2020, 20,017 will vest on March 2, 2021 and 20,018 will vest on March 2, 2022.

SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 9

Malik Rajiv · CIK 0001388111 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,225

Underlying: Common Stock · 73,225 shares

Expires not disclosed

F11 · security: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F12 · price: Received in exchange for, and having substantially the same terms as (other than no longer being subject to the performance-based vesting conditions), performance restricted stock units of Mylan in connection with the Combination.

F11 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F11 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 8

Malik Rajiv · CIK 0001388111 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,645

Underlying: Common Stock · 14,645 shares

Expires not disclosed

F9 · security: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021.

F10 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F11 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F11 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 7

Malik Rajiv · CIK 0001388111 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,600

Underlying: Common Stock · 71,600 shares

Expires 2028-03-02

F3 · security: Includes 620 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F9 · derivative.exercise_date: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021.

SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 6

Malik Rajiv · CIK 0001388111 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,574

Underlying: Common Stock · 65,574 shares

Expires 2027-03-03

F3 · security: Includes 620 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F8 · derivative.exercise_date: These options vested on March 3, 2020.

SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 5

Malik Rajiv · CIK 0001388111 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,168

Underlying: Common Stock · 50,168 shares

Expires 2026-02-17

F3 · security: Includes 620 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F7 · derivative.exercise_date: These options vested on February 17, 2019.

SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 4

Malik Rajiv · CIK 0001388111 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,637

Underlying: Common Stock · 41,637 shares

Expires 2025-11-17

F3 · security: Includes 620 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F6 · derivative.exercise_date: These options vested on March 4, 2018.

SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 3

Malik Rajiv · CIK 0001388111 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,389

Underlying: Common Stock · 34,389 shares

Expires 2024-03-05

F3 · security: Includes 620 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F5 · derivative.exercise_date: These options vested on March 5, 2017.

SEC source: 0000899243-20-031559 · doc4.xml · nonDerivative · entry 2

Malik Rajiv · CIK 0001388111 · Director · President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Grantor Retained Annuity Trust

Disclosed balance after: 88,365

F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

SEC source: 0000899243-20-031559 · doc4.xml · nonDerivative · entry 1

Malik Rajiv · CIK 0001388111 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 460,319

F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

F3 · balance_after: Includes 620 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

SEC source: 0000899243-20-031576 · doc4.xml · derivative · entry 10

Lyons Dillon JoEllen · CIK 0001570168 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,440

Underlying: Common Stock · 9,440 shares

Expires not disclosed

F12 · security: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F12 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F13 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F13 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

SEC source: 0000899243-20-031576 · doc4.xml · derivative · entry 9

Lyons Dillon JoEllen · CIK 0001570168 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,151

Underlying: Common Stock · 6,151 shares

Expires 2030-03-02

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F11 · derivative.exercise_date: These options will vest on March 2, 2021.

SEC source: 0000899243-20-031576 · doc4.xml · derivative · entry 8

Lyons Dillon JoEllen · CIK 0001570168 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,352

Underlying: Common Stock · 4,352 shares

Expires 2029-03-01

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F10 · derivative.exercise_date: These options vested on March 2, 2020.

SEC source: 0000899243-20-031576 · doc4.xml · derivative · entry 7

Lyons Dillon JoEllen · CIK 0001570168 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,984

Underlying: Common Stock · 2,984 shares

Expires 2028-03-02

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F9 · derivative.exercise_date: These options vested on March 2, 2019.

SEC source: 0000899243-20-031576 · doc4.xml · derivative · entry 6

Lyons Dillon JoEllen · CIK 0001570168 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,928

Underlying: Common Stock · 2,928 shares

Expires 2027-03-03

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F8 · derivative.exercise_date: These options vested on March 3, 2018.

SEC source: 0000899243-20-031576 · doc4.xml · derivative · entry 5

Lyons Dillon JoEllen · CIK 0001570168 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,788

Underlying: Common Stock · 2,788 shares

Expires 2026-02-17

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F7 · derivative.exercise_date: These options vested on February 17, 2017.

SEC source: 0000899243-20-031576 · doc4.xml · derivative · entry 4

Lyons Dillon JoEllen · CIK 0001570168 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,603

Underlying: Common Stock · 2,603 shares

Expires 2025-11-17

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F6 · derivative.exercise_date: These options vested on May 1, 2016.

SEC source: 0000899243-20-031576 · doc4.xml · derivative · entry 3

Lyons Dillon JoEllen · CIK 0001570168 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,974

Underlying: Common Stock · 2,974 shares

Expires 2024-04-11

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F5 · derivative.exercise_date: These options vested on April 11, 2015.

SEC source: 0000899243-20-031576 · doc4.xml · nonDerivative · entry 1

Lyons Dillon JoEllen · CIK 0001570168 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,609

F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 29

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 933

Underlying: Common Stock · 933 shares

Expires not disclosed

F15 · security: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F16 · price: Received in exchange for, and having substantially the same terms as (other than no longer being subject to the performance-based vesting conditions), performance restricted stock units of Mylan in connection with the Combination.

F25 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2023.

F25 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2023.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 28

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,744

Underlying: Common Stock · 25,744 shares

Expires not disclosed

F15 · security: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F16 · price: Received in exchange for, and having substantially the same terms as (other than no longer being subject to the performance-based vesting conditions), performance restricted stock units of Mylan in connection with the Combination.

F25 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2023.

F25 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2023.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 27

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 1,866

Underlying: Common Stock · 1,866 shares

Expires not disclosed

F13 · security: One-third of these options vested on each of March 2, 2019 and March 2, 2020 and one-third will vest on March 2, 2021.

F14 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F24 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest in three equal annual installments beginning on March 2, 2021.

F24 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest in three equal annual installments beginning on March 2, 2021.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 26

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,595

Underlying: Common Stock · 20,595 shares

Expires not disclosed

F13 · security: One-third of these options vested on each of March 2, 2019 and March 2, 2020 and one-third will vest on March 2, 2021.

F14 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F24 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest in three equal annual installments beginning on March 2, 2021.

F24 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest in three equal annual installments beginning on March 2, 2021.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 25

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 669

Underlying: Common Stock · 669 shares

Expires 2030-03-02

F3 · security: Includes 84 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F23 · derivative.exercise_date: These options will vest in three equal annual installments beginning on March 2, 2021.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 24

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,071

Underlying: Common Stock · 11,071 shares

Expires 2030-03-02

F3 · security: Includes 84 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F22 · derivative.exercise_date: 3,691 of these options will vest on March 2, 2021 and 3,690 will vest on each of March 2, 2022 and March 2, 2023.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 23

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 577

Underlying: Common Stock · 577 shares

Expires not disclosed

F15 · security: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F16 · price: Received in exchange for, and having substantially the same terms as (other than no longer being subject to the performance-based vesting conditions), performance restricted stock units of Mylan in connection with the Combination.

F21 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2022.

F21 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2022.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 22

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,483

Underlying: Common Stock · 15,483 shares

Expires not disclosed

F15 · security: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F16 · price: Received in exchange for, and having substantially the same terms as (other than no longer being subject to the performance-based vesting conditions), performance restricted stock units of Mylan in connection with the Combination.

F21 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2022.

F21 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2022.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 21

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 770

Underlying: Common Stock · 770 shares

Expires not disclosed

F13 · security: One-third of these options vested on each of March 2, 2019 and March 2, 2020 and one-third will vest on March 2, 2021.

F14 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F20 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. 385 of the RSUs will vest on each of March 2, 2021 and March 2, 2022.

F20 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. 385 of the RSUs will vest on each of March 2, 2021 and March 2, 2022.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 20

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,258

Underlying: Common Stock · 8,258 shares

Expires not disclosed

F13 · security: One-third of these options vested on each of March 2, 2019 and March 2, 2020 and one-third will vest on March 2, 2021.

F14 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F19 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. 4,129 of the RSUs will vest on each of March 2, 2021 and March 2, 2022.

F19 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. 4,129 of the RSUs will vest on each of March 2, 2021 and March 2, 2022.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 19

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 460

Underlying: Common Stock · 460 shares

Expires 2029-03-01

F3 · security: Includes 84 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F18 · derivative.exercise_date: 154 of these options vested on March 2, 2020 and 153 will vest on each of March 2, 2021 and March 2, 2022.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 18

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,398

Underlying: Common Stock · 7,398 shares

Expires 2029-03-01

F3 · security: Includes 84 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F17 · derivative.exercise_date: One-third of these options vested on March 2, 2020 and one-third will vest on each of March 2, 2021 and March 2, 2022.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 17

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 501

Underlying: Common Stock · 501 shares

Expires not disclosed

F15 · security: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F16 · price: Received in exchange for, and having substantially the same terms as (other than no longer being subject to the performance-based vesting conditions), performance restricted stock units of Mylan in connection with the Combination.

F15 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F15 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 16

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,900

Underlying: Common Stock · 9,900 shares

Expires not disclosed

F15 · security: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F16 · price: Received in exchange for, and having substantially the same terms as (other than no longer being subject to the performance-based vesting conditions), performance restricted stock units of Mylan in connection with the Combination.

F15 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F15 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 15

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 167

Underlying: Common Stock · 167 shares

Expires not disclosed

F13 · security: One-third of these options vested on each of March 2, 2019 and March 2, 2020 and one-third will vest on March 2, 2021.

F14 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F15 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F15 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 14

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,980

Underlying: Common Stock · 1,980 shares

Expires not disclosed

F13 · security: One-third of these options vested on each of March 2, 2019 and March 2, 2020 and one-third will vest on March 2, 2021.

F14 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F15 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F15 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 13

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 612

Underlying: Common Stock · 612 shares

Expires 2028-03-02

F3 · security: Includes 84 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F13 · derivative.exercise_date: One-third of these options vested on each of March 2, 2019 and March 2, 2020 and one-third will vest on March 2, 2021.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 12

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,681

Underlying: Common Stock · 9,681 shares

Expires 2028-03-02

F3 · security: Includes 84 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F13 · derivative.exercise_date: One-third of these options vested on each of March 2, 2019 and March 2, 2020 and one-third will vest on March 2, 2021.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 11

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,392

Underlying: Common Stock · 4,392 shares

Expires 2027-03-03

F3 · security: Includes 84 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F12 · derivative.exercise_date: These options vested on March 3, 2020.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 10

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,181

Underlying: Common Stock · 4,181 shares

Expires 2026-02-17

F3 · security: Includes 84 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F11 · derivative.exercise_date: These options vested on February 17, 2019.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 9

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,059

Underlying: Common Stock · 2,059 shares

Expires 2025-03-04

F3 · security: Includes 84 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F10 · derivative.exercise_date: These options vested on March 4, 2018.